1 August 2024 false No description of principal activity Taxfiler 2024.6 12456898business:PrivateLimitedCompanyLtd2024-08-012025-07-31 124568982024-07-31 124568982024-08-012025-07-31 12456898business:AuditExempt-NoAccountantsReport2024-08-012025-07-31 12456898business:FilletedAccounts2024-08-012025-07-31 124568982025-07-31 12456898business:Director12024-08-012025-07-31 12456898business:RegisteredOffice2024-08-012025-07-31 124568982024-07-31 12456898core:WithinOneYear2025-07-31 12456898core:WithinOneYear2024-07-31 12456898core:AfterOneYear2025-07-31 12456898core:AfterOneYear2024-07-31 12456898core:ShareCapitalcore:PreviouslyStatedAmount2025-07-31 12456898core:ShareCapitalcore:PreviouslyStatedAmount2024-07-31 12456898core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-07-31 12456898core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-07-31 12456898core:PreviouslyStatedAmount2025-07-31 12456898core:PreviouslyStatedAmount2024-07-31 12456898business:SmallEntities2024-08-012025-07-31 12456898countries:EnglandWales2024-08-012025-07-31 12456898core:PlantMachinery2024-07-31 12456898core:FurnitureFittings2024-07-31 12456898core:ComputerEquipment2024-07-31 12456898core:PlantMachinery2024-08-012025-07-31 12456898core:FurnitureFittings2024-08-012025-07-31 12456898core:ComputerEquipment2024-08-012025-07-31 12456898core:PlantMachinery2025-07-31 12456898core:FurnitureFittings2025-07-31 12456898core:ComputerEquipment2025-07-31 124568982023-08-012024-07-31 iso4217:GBP xbrli:pure
Company Registration No. 12456898 (England and Wales)
INTEGRAL BIOPHARMA LTD Unaudited accounts for the year ended 31 July 2025
INTEGRAL BIOPHARMA LTD Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
INTEGRAL BIOPHARMA LTD Company Information for the year ended 31 July 2025
Director
R Mahmood
Company Number
12456898 (England and Wales)
Registered Office
UNIT B THAMES HOUSE THAMES STREET ROTHERHAM S60 1LU ENGLAND
- 3 -
INTEGRAL BIOPHARMA LTD Statement of financial position as at 31 July 2025
2025 
2024 
Notes
£ 
£ 
Fixed assets
Tangible assets
4
76,755 
37,705 
Current assets
Debtors
5
17,026 
13,954 
Cash at bank and in hand
76,286 
165,407 
93,312 
179,361 
Creditors: amounts falling due within one year
6
(3,853)
(15,860)
Net current assets
89,459 
163,501 
Total assets less current liabilities
166,214 
201,206 
Creditors: amounts falling due after more than one year
7
(92,000)
- 
Net assets
74,214 
201,206 
Capital and reserves
Called up share capital
100 
100 
Profit and loss account
74,114 
201,106 
Shareholders' funds
74,214 
201,206 
For the year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 29 July 2026 and were signed on its behalf by
R Mahmood Director Company Registration No. 12456898
- 4 -
INTEGRAL BIOPHARMA LTD Notes to the Accounts for the year ended 31 July 2025
1
Statutory information
INTEGRAL BIOPHARMA LTD is a private company, limited by shares, registered in England and Wales, registration number 12456898. The registered office is UNIT B THAMES HOUSE, THAMES STREET, ROTHERHAM, S60 1LU, ENGLAND.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
4
Tangible fixed assets
Plant & machinery 
Fixtures & fittings 
Computer equipment 
Total 
£ 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At cost 
At 1 August 2024
86,400 
6,328 
3,551 
96,279 
Additions
54,021 
500 
1,054 
55,575 
At 31 July 2025
140,421 
6,828 
4,605 
151,854 
Depreciation
At 1 August 2024
51,840 
4,748 
1,986 
58,574 
Charge for the year
15,280 
316 
929 
16,525 
At 31 July 2025
67,120 
5,064 
2,915 
75,099 
Net book value
At 31 July 2025
73,301 
1,764 
1,690 
76,755 
At 31 July 2024
34,560 
1,580 
1,565 
37,705 
5
Debtors
2025 
2024 
£ 
£ 
Amounts falling due within one year
VAT
2,348 
- 
Trade debtors
9,127 
8,132 
Accrued income and prepayments
4,005 
4,005 
Other debtors
1,546 
1,817 
17,026 
13,954 
- 5 -
INTEGRAL BIOPHARMA LTD Notes to the Accounts for the year ended 31 July 2025
6
Creditors: amounts falling due within one year
2025 
2024 
£ 
£ 
Taxes and social security
472 
13,176 
Other creditors
1,132 
435 
Accruals
2,249 
2,249 
3,853 
15,860 
7
Creditors: amounts falling due after more than one year
2025 
2024 
£ 
£ 
Loans from directors
92,000 
- 
8
Average number of employees
During the year the average number of employees was 3 (2024: 3).
- 6 -